Reneuron

1

Our Technologies

our_technology

Our stem cell expansion and screening technologies have enabled us to generate quality-assured stem cell lines in quantities sufficient to treat many hundreds of thousands of potential patients. Read More ....

 

Subscribe here for our Press Releases

Our Products

  our_products

We have developed stem cell therapies for serious conditions such as stroke disability where the patient populations are significant and where few if any alternative treatments exist. Read More ....

Share Price

To view detailed share price information
for ReNeuron Group plc. Click Here

Latest News

Guildford, UK, 15 April 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L), the leading UK-based stem cell therapy company, is pleased to announce that it has signed an agreement with the Welsh Government to lease a
Guildford, UK, 27 March 2014: ReNeuron Group plc (the "Company") (AIM: RENE.L), a leading UK-based stem cell therapy company, is pleased to announce that it has received final UK regulatory and ethical approvals to commence two
Guildford, UK, 14 March 2014:  ReNeuron Group plc, a leading UK-based stem cell therapy company, welcomes today’s announcement from the UK Government Department of Health of the launch of the Early Access to Medicines

ReNeuron is a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Read more ....

ReNeuron welcomes launch of UK Government Early Access to Medicines Scheme

PDFPrintE-mail

Guildford, UK, 14 March 2014:  ReNeuron Group plc, a leading UK-based stem cell therapy company, welcomes today’s announcement from the UK Government Department of Health of the launch of the Early Access to Medicines Scheme (EAMS).

Read more...
 

©ReNeuron Group plc 2005-2013 All rights reserved

Privacy                Disclaimer